Search results
Results From The WOW.Com Content Network
Lonza Group Ag (LZAGY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
lonza.com. Lonza Group AG is a Swiss multinational manufacturing company for the pharmaceutical, biotechnology and nutrition sectors, headquartered in Basel, with major facilities in Europe, North America and South Asia. Lonza was established under that name in the late 19th-century in Switzerland. The company provides product development ...
Lonza Group Ltd (VTX:LONN) saw a double-digit share price rise of over 10% in the past couple of months on the SWX...
The size of Lonza Group Ltd (VTX:LONN), a CHF22b large-cap, often attracts investors seeking a reliable investment in the stock market. Market participants who are conscious of risk tend to search ...
Actelion replaced by Lonza Group after Actelion's purchase by Johnson & Johnson. [20] In the same month, Sika AG replaced Syngenta after its purchase by ChemChina. [21] June 2018: Sika announced a 1:60 stock split. [22] Before this change, it was the SMI constituent with the highest price per share. April 2019
The stock of Lonza Group (OTCPK:LZAGY, 30-year Financials) is believed to be significantly overvalued, according to GuruFocus Value calculation.
Cambrex Corporation is a Contract Development Manufacturing Organisation (CDMO) that provides drug substance, drug product and analytical services across the entire drug lifecycle, as well as active pharmaceutical ingredients (APIs). With over 2,200 employees in 7 countries across 13 locations, Cambrex operates in branded and generic markets ...
After Lonza Group Ltd's (VTX:LONN) earnings announcement in December 2018, analysts seem cautiously optimistic, as a...